Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orfadin Once vs Twice Daily Dosing in HT-1
NCT02323529Phase 3Completed
- Sponsor
- Sobi
- Start
- Dec 2014
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of nitisinone in hereditary tyrosinemia type 1 (HT1), sponsored by Sobi. Started Dec 2014; status: completed.
02
Drugs
nitisinone
03
Conditions
hereditary tyrosinemia type 1 (HT1)
Beyond the preview
Go deeper on NCT02323529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02323529.